Rapport Therapeutics (RAPP) Operating Income (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Operating Income data on file, last reported at -$24.2 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$24.2 million, up 10.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$122.2 million (down 31.31% YoY), and the FY2025 annual result was -$125.1 million, down 50.62% from the prior year.
• Operating Income improved to -$24.2 million in Q1 2026 per RAPP's latest filing, from -$38.5 million in the prior quarter.
• Over five years, Operating Income peaked at -$6.6 million in Q2 2023 and troughed at -$38.5 million in Q4 2025.
• A 4-year average of -$21.9 million and a median of -$22.6 million in 2024 frame the typical range for Operating Income.
• The sharpest annual moves came in 2024 and 2026: Operating Income slumped 213.73% in 2024, then advanced 10.67% in 2026.
• A 4-year view of Operating Income shows it stood at -$14.8 million in 2023, then plunged by 58.99% to -$23.5 million in 2024, then plunged by 63.72% to -$38.5 million in 2025, then surged by 37.12% to -$24.2 million in 2026.
• Business Quant data shows RAPP's Operating Income at -$24.2 million in Q1 2026, -$38.5 million in Q4 2025, and -$30.0 million in Q3 2025.